内容由MediCom Oncology提供。所有播客内容(包括剧集、图形和播客描述)均由 MediCom Oncology 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal。
Player FM -播客应用
使用Player FM应用程序离线!
使用Player FM应用程序离线!
值得一听的播客
赞助
<
<div class="span index">1</div> <span><a class="" data-remote="true" data-type="html" href="/series/lipstick-on-the-rim">Lipstick on the Rim</a></span>


Consider Molly Sims and her best friend Emese Gormley your new girlfriends on speed dial for all your pressing beauty and wellness needs. Is Botox a good idea? Should you try that new diet you saw on the Today Show? Molly and Emese have your back. With guests ranging from top health and beauty experts to their industry friends, you’ll get the scoop on the latest trends, which products and procedures to try, and which to run from-- and they just might be doing it all with a drink in hand. Prepare to be obsessed.
Standard dosing and delivery of FOLFIRINOX
Manage episode 178003681 series 1375096
内容由MediCom Oncology提供。所有播客内容(包括剧集、图形和播客描述)均由 MediCom Oncology 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal。
Listen as Dr. Andrea Wang-Gillam explains standard dosing and delivery of FOLFIRNOX in patients with pancreatic cancer.
…
continue reading
53集单集
Manage episode 178003681 series 1375096
内容由MediCom Oncology提供。所有播客内容(包括剧集、图形和播客描述)均由 MediCom Oncology 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal。
Listen as Dr. Andrea Wang-Gillam explains standard dosing and delivery of FOLFIRNOX in patients with pancreatic cancer.
…
continue reading
53集单集
Wszystkie odcinki
×Dr. Perl provides a brief summary of what is on the horizon for FLT3 inhibitors in AML.
Dr. Sallman describes a patient case demonstrating promise in the further study and potential use of CAR T-cell therapy for patients with AML.
Dr. Perl gives guidance on providing optimal patient therapy when prescribing midostaurin with a strong CYP3A4 inhibitor.

1 How to proceed with a patient who presents with idiopathic cytopenia of undetermined significance 3:58
In this audio activity, Dr. Goldberg describes his approach to patients with idiopathic or clonal cytopenias of undetermined significance (ICUS and CCUS).
Listen as Dr. Goldberg explains his approach to iron chelation therapy in patients who are, or may be within the next 5-10 years, eligible for transplant.
Hematopathologist Dr. Khoury presents a case snapshot showing the complexities of diagnosing AML, describing the importance of morphology, flow cytometry, cytogenetics, and molecular diagnostics.
Dr. O'Reilly discusses the new subcategories of pancreatic cancer that have emerged, and which are laying the groundwork for a biomarker-driven approach to therapy.

1 What are the unique aspects of pancreas cancer that lead to the development of novel therapeutics? 2:40
Dr. O'Reilly discusses the unique pathophysiology of pancreas cancer that must be considered in the development of novel therapeutics.
Listen as Dr. Goldberg discusses, in just under two minutes, the predictors of response to lenalidomide in a non-del(5q) MDS patient.
Listen as Dr. Matasar discusses the pros and cons of radiation therapy, and who should be offered this therapy.

1 What defines high-quality survivorship care for patients treated for classical Hodgkin lymphoma? 3:01
Listen as Dr. Matasar discusses survivorship care for patients who have been treated for classical Hodgkin lymphoma, including late effects of treatment.
Dr. Jacob Laubach discusses second primary malignancies associated with lenalidomide maintenance in the transplant and post-transplant setting.
Dr. Laubach discusses the impact of consolidation therapy in patients post-transplant, referencing results of the CTN StaMINA trial.
Dr. Jacob Laubach discusses bortezomib as an alternate strategy to lenalidomide for maintenance therapy in patients with multiple myeloma.
Listen as Dr. Matasar discusses the future role of brentuximab vedotin in patients with newly diagnosed classical Hodgkin lymphoma.
M
MediCom Oncology Clinical Pearls Podcasts

Dr. Ruben Niesvizky discusses MRD testing and how it has become a standard of care in multiple myeloma, as well as future directions in MRD testing that will improve outcomes in these patients.
M
MediCom Oncology Clinical Pearls Podcasts

Dr. O'Reilly provides an insightful overview of how the emerging use of precision medicine and the Precision Promise [SM] initiative will impact the new drug approval process in pancreatic cancer.
M
MediCom Oncology Clinical Pearls Podcasts

Dr. Eytan Stein provides a brief update on phase 1 arms of a trial studying the effectiveness of enasidenib in patients with relapsed and refractory AML and an IDH2 mutation.
M
MediCom Oncology Clinical Pearls Podcasts

1 What are the optimal imaging methods to determine extent of bone disease in newly diagnosed MM? 3:18
Dr. Ruben Niesvizky discusses newer approaches for imaging in patients who have multiple myeloma with bone disease, including the benefits of combining modalities such MRI and PET scan.
M
MediCom Oncology Clinical Pearls Podcasts

1 The standard of care for patients receiving lenalidomide or thalidomide who are at high risk for VTE 3:36
Dr. Ruben Niesvizky discusses clinical approaches to managing the risk of developing VTE in myeloma patients receiving immunomodulating agents such as lenalidomide or thalidomide.
M
MediCom Oncology Clinical Pearls Podcasts

In under two minutes, Dr. Carol Ann Huff will discuss how to dose daratumumab in conjunction with lenalidomide and dexamethasone in patients with multiple myeloma.
M
MediCom Oncology Clinical Pearls Podcasts

Dr. Anil Rustgi discusses a clinical prediction model to assess risk for pancreatic cancer among patients with new-onset diabetes.
M
MediCom Oncology Clinical Pearls Podcasts

Dr. Stuart Goldberg briefly summarizes updates on CPX-351, a liposomal form of cytarabine and daunorubicin that allows for office infusion vs. standard consolidation requiring hospitalization.
M
MediCom Oncology Clinical Pearls Podcasts

Listen as Dr. Huff discusses the infusion duration for carfilzomib in patients with multiple myeloma.
M
MediCom Oncology Clinical Pearls Podcasts

Listen as Dr. O'Reilly discusses the the current status of immunotherapy in pancreatic cancer.
M
MediCom Oncology Clinical Pearls Podcasts

Listen for just under two minutes as Dr. Harvey explains measuring frailty in patients being treated for multiple myeloma.
M
MediCom Oncology Clinical Pearls Podcasts

Dr. Eytan Stein provides a brief update on patients experiencing differentiation syndrome in a larger enasidenib trial, detailing the creation of a Differentiation Syndrome Review Committee.
M
MediCom Oncology Clinical Pearls Podcasts

Listen as Dr. Carol Ann Huff discusses how to dose daratumumab, bortezomib and dexamethasone in the combination regimen.
M
MediCom Oncology Clinical Pearls Podcasts

Listen as Dr. Philip McCarthy provides an update on the CALGB-100104 (Alliance) randomized trial.
M
MediCom Oncology Clinical Pearls Podcasts

1 How does the safety profile of the new and emerging anti-PD 1 antibodies differ from chemotherapy? 1:55
Listen as Dr. Alison Moskowitz discusses the difference between the safety profile of the new and emerging anti-PD-1 antibodies and chemotherapy.
欢迎使用Player FM
Player FM正在网上搜索高质量的播客,以便您现在享受。它是最好的播客应用程序,适用于安卓、iPhone和网络。注册以跨设备同步订阅。